Chemotherapy response criteria in malignant glioma

Neurology

Volumn 48, Issue 5, 1997, Pages 1336-1340

  Grant, Robert ^a   Liang, B C ^b   Slattery, J ^a   Greenberg, H S ^c   Junck, L ^c  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; HYDROXYUREA; LOMUSTINE; NITROSOUREA; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GLIOBLASTOMA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0030965006     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.5.1336     Document Type: Article

References (18)

1. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluoro-uracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
3. Zulch KJ. Histological typing of tumors of the central nervous system. Geneva, Switzerland: World Health Organization, 1979.
4. Newton HB, Junck L, Bromberg J. Page MA, Greenberg HS. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosurea failure. Neurology 1990;40:1743-1746.
5. Grant R, Liang BC, Page MA, Crane DL, Greenberg HS, Junck L. Age influences chemotherapy response in astrocytomas. Neurology 1995;45:929-933.
6. Taylor SA, Upchurch C, Goodwin W, et al. Assessment of the response to new agents for primary CNS malignancies. Proc Am Soc Clin Oncol 1993;12:176.
7. Cairncross JG, Eisenhauer EA. Response and control: lessons from oligodendroglioma. J Clin Oncol 1995;13:2475.
8. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23: 360-364.
9. Murovic J, Turowski K, Wilson CB, et al. Computerized tomography in the prognosis of malignant cerebral gliomas. J Neurosurg 1986;65:799-806.
10. Bhuyan BK, Smith KS, Adams EG, Petzold GL, Mcgovren JP. Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells. Cancer Res 1992;52: 5687-5692.
11. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a co-operative clinical trial. J Neurosurg 1978;49:333-343.
12. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303: 1323-1329.
13. Green SB, Byar D, Walker MD, et al. Comparisons of carmustine, procarbazine and high dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983;67:121-132.
14. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined post-operative radiotherapy and chemotherapy in the multidisciplinary management of malignant glioma: a joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology group study. Cancer 1983;52:997-1007.
15. Zelter PM, Friedman HS, Norris DG, et al. Criteria and definition of response and relapse in children with brain tumor. Cancer 1985;56:1824-1826.
16. Warr D, McKinney S, Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol 1984;2:1040-1046.
17. Cairncross JG, Pexman JHW, Rathbone MP. Post-surgical contrast enhancement mimicking residual brain tumor. Can J Neurol Sci 1985;12:75.
18. Cascino TL, Kimmel DW, Dinapoli RP, et al. Report of four cases with a resolving syndrome which otherwise simulates recurrent brain tumor. Neurology 1989;39:62-65.